Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

287
25
Favorite

Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

Benzinga2021-08-23

The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above. Gvoke Kit is the first ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

287

Report

Comment（25）

El_Nino
·2021-08-24
Like n comment pls
Reply
Like
Report
henghm
·2021-08-24
Likes and comment
Reply
Like
Report
Fold Replies
- Kentlieu:
  Ok
  2021-08-24
  Reply
  Report
MingXuan
·2021-08-24
Hi
Reply
1
Report
Timevestor
·2021-08-24
Please like and comment.
Reply
2
Report
Bonghanhuei
·2021-08-24
Good
Reply
3
Report
Fold Replies
- Ezumu:
  y
  2021-08-24
  Reply
  Report
我不是股神我是赌神
·2021-08-24
Ok
Reply
2
Report
Fold Replies
- Bonghanhuei:
  ok
  2021-08-24
  Reply
  Report
Sunshine88
·2021-08-24
Like please
Reply
5
Report
Fold Replies
- RK888:
  Done
  2021-08-24
  Reply
  Report
SkyLim
·2021-08-24
Ok
Reply
4
Report
Daleo
·2021-08-24
Shining
Reply
4
Report
klo
·2021-08-24
K
Reply
4
Report
Fold Replies
- Keychain:
  Done
  2021-08-24
  Reply
  Report
- Daleo:
  Like
  2021-08-24
  Reply
  Report
Jassss
·2021-08-24
Like
Reply
6
Report
MrMrsBean
·2021-08-24
Please like and comment. Thanks
Reply
6
Report
Fold Replies
- shawnhuat:
  ok
  2021-08-24
  Reply
  Report
Kalpana
·2021-08-24
Ok
Reply
7
Report
Bodoh
·2021-08-24
Shining and price drop
Reply
8
Report
Sunny0809
·2021-08-24
Ok
Reply
6
Report
Fold Replies
- Kalpana:
  ?
  2021-08-24
  Reply
  Report
- SkyLim:
  ok
  2021-08-24
  Reply
  Report
Kcs
·2021-08-24
Like pls
Reply
7
Report
Fold Replies
- TyroneTy:
  [Smile]
  2021-08-24
  Reply
  Report
- Sunny0809:
  Ok
  2021-08-24
  Reply
  Report
- DarkRaven:
  Done
  2021-08-24
  Reply
  Report
View more 1 comments
jyip93
·2021-08-24
Like and comment
Reply
4
Report
Fold Replies
- Pplymm:
  Done. Pls like back
  2021-08-24
  Reply
  Report
Annalz
·2021-08-24
Time for medi care save ?️‍♂️?️‍♂️human being
Reply
2
Report
Fold Replies
- jyip93:
  Like and comment
  2021-08-24
  Reply
  Report
晓MIIN
·2021-08-24
?
Reply
2
Report
PeiYi99
·2021-08-24
Like
Reply
4
Report
Fold Replies
- Pplymm:
  Done. pls like back
  2021-08-24
  Reply
  Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-23 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130387472","market":"us","top_or_hot":-1,"title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","media":"Benzinga","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":null,"article_id":"1130387472","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","pubTimestamp":1629732233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"为什么Xeris Pharmaceuticals(XERS)的股票在周一闪亮","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":0.9},"content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":834002889,"gmtCreate":1629760460941,"gmtModify":1676530120154,"author":{"id":"3579591519090572","authorId":"3579591519090572","name":"El_Nino","avatar":"https://static.tigerbbs.com/6b1b731af69caf76640812930188d9d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3579591519090572","authorIdStr":"3579591519090572"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834002889","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834003772,"gmtCreate":1629760306796,"gmtModify":1676530120009,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3578451349447391","authorIdStr":"3578451349447391"},"htmlText":"Likes and comment","listText":"Likes and comment","text":"Likes and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834003772","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625962,"gmtCreate":1629760374429,"gmtModify":1663232811426,"authorId":3570093481697004,"author":{"id":3570093481697004,"idStr":"3570093481697004","authorId":3570093481697004,"name":"Kentlieu","avatar":"https://static.tigerbbs.com/ae3ee305e39da5ce2f99805f9a422c93","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":834003772,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":835777139,"gmtCreate":1629760082021,"gmtModify":1676530119929,"author":{"id":"3568776369893575","authorId":"3568776369893575","name":"MingXuan","avatar":"https://community-static.tradeup.com/news/37c7c3a638bb241a3e8ff139e1c00b0d","vip":1,"crmLevel":12,"crmLevelSwitch":1,"wearingBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"idStr":"3568776369893575","authorIdStr":"3568776369893575"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835777139","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835744641,"gmtCreate":1629759187983,"gmtModify":1676530119703,"author":{"id":"4087996122770160","authorId":"4087996122770160","name":"Timevestor","avatar":"https://community-static.tradeup.com/news/c445ff3f9f42cdd220e3e38056182334","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"4087996122770160","authorIdStr":"4087996122770160"},"htmlText":"Please like and comment.&nbsp;","listText":"Please like and comment.&nbsp;","text":"Please like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835744641","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835745781,"gmtCreate":1629759160143,"gmtModify":1676530119684,"author":{"id":"3581734044994294","authorId":"3581734044994294","name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3581734044994294","authorIdStr":"3581734044994294"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835745781","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625898,"gmtCreate":1629760065493,"gmtModify":1663232812655,"authorId":3570054700580513,"author":{"id":3570054700580513,"idStr":"3570054700580513","authorId":3570054700580513,"name":"Ezumu","avatar":"https://static.tigerbbs.com/376f19a6fd4e4be2d9304e4751c4eca8","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835745781,"type":1,"supId":0,"prevId":0,"content":"y","text":"y","html":"y"}],"langContent":"EN"},{"id":835746764,"gmtCreate":1629759013858,"gmtModify":1676530119632,"author":{"id":"3581643164424811","authorId":"3581643164424811","name":"我不是股神我是赌神","avatar":"https://static.tigerbbs.com/7e971ed6e3f7b6495a07f7b9b5007ee5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3581643164424811","authorIdStr":"3581643164424811"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835746764","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625726,"gmtCreate":1629759149586,"gmtModify":1663232815634,"authorId":3581734044994294,"author":{"id":3581734044994294,"idStr":"3581734044994294","authorId":3581734044994294,"name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835746764,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":835722325,"gmtCreate":1629757253367,"gmtModify":1676530119109,"author":{"id":"3586140387931872","authorId":"3586140387931872","name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3586140387931872","authorIdStr":"3586140387931872"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835722325","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625675,"gmtCreate":1629758858207,"gmtModify":1663232812641,"authorId":3584063721837527,"author":{"id":3584063721837527,"idStr":"3584063721837527","authorId":3584063721837527,"name":"RK888","avatar":"https://static.tigerbbs.com/c94493ec39af6df82d06fcfa8afb3483","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835722325,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":835726987,"gmtCreate":1629757171149,"gmtModify":1676530119086,"author":{"id":"3581901940644351","authorId":"3581901940644351","name":"SkyLim","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3581901940644351","authorIdStr":"3581901940644351"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835726987","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835721857,"gmtCreate":1629757003179,"gmtModify":1676530119039,"author":{"id":"3555197411237101","authorId":"3555197411237101","name":"Daleo","avatar":"https://static.tigerbbs.com/ba452052baf73339cd3641da48186831","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"1026c425416b44e0aac28c11a0848493-4","name":"Tiger Star","description":"Join the tiger community for 2000 days","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"idStr":"3555197411237101","authorIdStr":"3555197411237101"},"htmlText":"Shining&nbsp;","listText":"Shining&nbsp;","text":"Shining","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835721857","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835729676,"gmtCreate":1629756854495,"gmtModify":1676530119015,"author":{"id":"3583974243419968","authorId":"3583974243419968","name":"klo","avatar":"https://static.tigerbbs.com/e2d3dcf83877ea1c1bf83a2ba2b540df","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3583974243419968","authorIdStr":"3583974243419968"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835729676","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625615,"gmtCreate":1629758529950,"gmtModify":1663232810136,"authorId":3571801721484161,"author":{"id":3571801721484161,"idStr":"3571801721484161","authorId":3571801721484161,"name":"Keychain","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835729676,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5625381,"gmtCreate":1629756970283,"gmtModify":1663232809742,"authorId":3555197411237101,"author":{"id":3555197411237101,"idStr":"3555197411237101","authorId":3555197411237101,"name":"Daleo","avatar":"https://static.tigerbbs.com/ba452052baf73339cd3641da48186831","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.20","exceedPercentage":"80.69%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":1},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"1026c425416b44e0aac28c11a0848493-4","name":"Tiger Star","description":"Join the tiger community for 2000 days","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}]},"repliedAuthorId":0,"objectId":835729676,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":835762646,"gmtCreate":1629756419385,"gmtModify":1676530118881,"author":{"id":"3574244375315958","authorId":"3574244375315958","name":"Jassss","avatar":"https://static.tigerbbs.com/a1a74261bc0d795b37c8c963ee5393f0","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3574244375315958","authorIdStr":"3574244375315958"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835762646","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835766921,"gmtCreate":1629756258763,"gmtModify":1676530118858,"author":{"id":"3571129545109571","authorId":"3571129545109571","name":"MrMrsBean","avatar":"https://static.tigerbbs.com/8f1ab99fec06884945521404915aec0e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3571129545109571","authorIdStr":"3571129545109571"},"htmlText":"Please like and comment. Thanks","listText":"Please like and comment. Thanks","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835766921","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625323,"gmtCreate":1629756430891,"gmtModify":1663232811745,"authorId":3575420754880245,"author":{"id":3575420754880245,"idStr":"3575420754880245","authorId":3575420754880245,"name":"shawnhuat","avatar":"https://static.tigerbbs.com/ce96f5461b1fd7c34fc7f8592a7eb525","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835766921,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":835784630,"gmtCreate":1629755494320,"gmtModify":1676530118632,"author":{"id":"3583487187442003","authorId":"3583487187442003","name":"Kalpana","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3583487187442003","authorIdStr":"3583487187442003"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835784630","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835785814,"gmtCreate":1629755380138,"gmtModify":1676530118587,"author":{"id":"3559859558754319","authorId":"3559859558754319","name":"Bodoh","avatar":"https://static.tigerbbs.com/349218ea2852130ca86ce660b4aa2d59","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","name":"Tiger Star","description":"Join the tiger community for 2000 days","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"idStr":"3559859558754319","authorIdStr":"3559859558754319"},"htmlText":"Shining and price drop","listText":"Shining and price drop","text":"Shining and price drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835785814","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835782054,"gmtCreate":1629755260678,"gmtModify":1676530118556,"author":{"id":"3581539047362830","authorId":"3581539047362830","name":"Sunny0809","avatar":"https://static.tigerbbs.com/3ffb7aab0292fd1f17dfb9f99bc5eb03","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3581539047362830","authorIdStr":"3581539047362830"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835782054","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625225,"gmtCreate":1629755514661,"gmtModify":1663232810739,"authorId":3583487187442003,"author":{"id":3583487187442003,"idStr":"3583487187442003","authorId":3583487187442003,"name":"Kalpana","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835782054,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"},{"id":5625406,"gmtCreate":1629757159668,"gmtModify":1663232809065,"authorId":3581901940644351,"author":{"id":3581901940644351,"idStr":"3581901940644351","authorId":3581901940644351,"name":"SkyLim","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835782054,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":835700253,"gmtCreate":1629737243772,"gmtModify":1676530117491,"author":{"id":"3584399321708796","authorId":"3584399321708796","name":"Kcs","avatar":"https://static.tigerbbs.com/d09d53be965ae7c58393d4b6cdd3c3af","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3584399321708796","authorIdStr":"3584399321708796"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/835700253","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625356,"gmtCreate":1629756748930,"gmtModify":1663232811531,"authorId":3581800583348951,"author":{"id":3581800583348951,"idStr":"3581800583348951","authorId":3581800583348951,"name":"TyroneTy","avatar":"https://static.tigerbbs.com/faea595be680e443c22d21f3209eaf0f","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","name":"Real Trader","description":"Completed a transaction","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}]},"repliedAuthorId":0,"objectId":835700253,"type":1,"supId":5625203,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]"},{"id":5625203,"gmtCreate":1629755272902,"gmtModify":1663232809148,"authorId":3581539047362830,"author":{"id":3581539047362830,"idStr":"3581539047362830","authorId":3581539047362830,"name":"Sunny0809","avatar":"https://static.tigerbbs.com/3ffb7aab0292fd1f17dfb9f99bc5eb03","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835700253,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5625116,"gmtCreate":1629754070082,"gmtModify":1663232808129,"authorId":3578097586468199,"author":{"id":3578097586468199,"idStr":"3578097586468199","authorId":3578097586468199,"name":"DarkRaven","avatar":"https://static.tigerbbs.com/f931425b992eebdac73826679fa69afc","vip":1,"currentWearingBadge":{"badgeId":"ab9f2a66a95942a38ebf4a8f8e47a915-1","templateUuid":"ab9f2a66a95942a38ebf4a8f8e47a915","name":"Super Discloser","description":"Enable Super Disclosure in TradeFeed","bigImgUrl":"https://community-static.tradeup.com/news/802f4014829adb4e63332fc230b97e42","smallImgUrl":"https://community-static.tradeup.com/news/70e97d213ed3e4f4820224f1366d402f","redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1104,"isScarce":0,"effectEnabled":0,"wearingSort":1},"crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"ab9f2a66a95942a38ebf4a8f8e47a915-1","name":"Super Discloser","description":"Enable Super Disclosure in TradeFeed","smallImgUrl":"https://community-static.tradeup.com/news/70e97d213ed3e4f4820224f1366d402f","bigImgUrl":"https://community-static.tradeup.com/news/802f4014829adb4e63332fc230b97e42","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000}]},"repliedAuthorId":0,"objectId":835700253,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5625099,"gmtCreate":1629753816572,"gmtModify":1663232808048,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835700253,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back","text":"Done. pls like back","html":"Done. pls like back"}],"langContent":"EN"},{"id":835477568,"gmtCreate":1629737114654,"gmtModify":1676530117481,"author":{"id":"3568615780432279","authorId":"3568615780432279","name":"jyip93","avatar":"https://static.tigerbbs.com/40bc8cd94658e02bab26b5fb8d25b2da","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3568615780432279","authorIdStr":"3568615780432279"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835477568","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625095,"gmtCreate":1629753796996,"gmtModify":1663232808145,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835477568,"type":1,"supId":0,"prevId":0,"content":"Done. Pls like back","text":"Done. Pls like back","html":"Done. Pls like back"}],"langContent":"EN"},{"id":835477013,"gmtCreate":1629736992532,"gmtModify":1676530117465,"author":{"id":"3577089953267281","authorId":"3577089953267281","name":"Annalz","avatar":"https://static.tigerbbs.com/ffd285ab6189bb61da4b48c3e149eedc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3577089953267281","authorIdStr":"3577089953267281"},"htmlText":"Time for&nbsp;medi care save ?️‍♂️?️‍♂️human being&nbsp;","listText":"Time for&nbsp;medi care save ?️‍♂️?️‍♂️human being&nbsp;","text":"Time for medi care save ?️‍♂️?️‍♂️human being","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835477013","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5624606,"gmtCreate":1629737124137,"gmtModify":1663232805748,"authorId":3568615780432279,"author":{"id":3568615780432279,"idStr":"3568615780432279","authorId":3568615780432279,"name":"jyip93","avatar":"https://static.tigerbbs.com/40bc8cd94658e02bab26b5fb8d25b2da","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835477013,"type":1,"supId":0,"prevId":0,"content":"Like and comment ","text":"Like and comment ","html":"Like and comment "}],"langContent":"EN"},{"id":835472522,"gmtCreate":1629736749166,"gmtModify":1676530117400,"author":{"id":"3573767135380290","authorId":"3573767135380290","name":"晓MIIN","avatar":"https://static.tigerbbs.com/9e223a6a40d05afa03fb58b646e13cd1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3573767135380290","authorIdStr":"3573767135380290"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835472522","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835441655,"gmtCreate":1629735053777,"gmtModify":1676530117029,"author":{"id":"3582637292455335","authorId":"3582637292455335","name":"PeiYi99","avatar":"https://static.tigerbbs.com/106de96bbc6719df0070ae1f2a3daa28","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3582637292455335","authorIdStr":"3582637292455335"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835441655","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=en_US&edition=fundamental","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-23 23:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5625100,"gmtCreate":1629753847584,"gmtModify":1663232807534,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":835441655,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back","text":"Done. pls like back","html":"Done. pls like back"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":287,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}